Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients
- Registration Number
- NCT03003143
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Age 18-85
- Possible autoimmune encephalitis
- Patients who have been diagnosed and treated for encephalitis for more than 4 weeks
- Patients with epilepsy (EEG finding or clinically)
Exclusion Criteria
- septic shock, fever >38.5 ℃, O2 saturation <90%, respiratory rate >25, HR >120
- previously, mRS=3 or mRS>3
- MMSE<20
- Patients who have terminal disease
- eye problem
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vigabatrin treatment group Vigabatrin 500 MG -
- Primary Outcome Measures
Name Time Method Seizure frequency reduction 3 month of vigabatrin administration 50% reduction - favorable outcome
- Secondary Outcome Measures
Name Time Method Depression (Beck Depression Inventory®-II) 3 month of vigabatrin administration Cognition (Mini-Mental State Examination-Korean) 3 month of vigabatrin administration Quality of life (Quality of Life in Epilepsy Inventory, QOLIE-31) after 3 month of vigabatrin administration Sleep quality (Pittsburgh Sleep Quality Assessment) 3 month of vigabatrin administration Modified Rankin Scale 3 month of vigabatrin administration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of GABA transaminase inhibition by Vigabatrin affect autoimmune encephalitis pathogenesis in NCT03003143?
How does Vigabatrin's efficacy in NCT03003143 compare to standard-of-care immunosuppressants like corticosteroids or IVIG for refractory autoimmune encephalitis?
Which biomarkers correlate with treatment response to Vigabatrin in GABA receptor antibody-positive autoimmune encephalopathy patients (NCT03003143)?
What are the incidence and management strategies for Vigabatrin-induced visual field defects in NCT03003143 autoimmune encephalitis participants?
Are there synergistic combination therapies involving Vigabatrin and anti-CD20 agents (e.g., rituximab) for treating refractory autoimmune encephalitis (NCT03003143)?
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital🇰🇷Seoul, Korea, Republic of